Table 3.
Comparison of levels of expression of KIR by predictor variable level
| Predictor variable | KIR 2DS2 Expression a | KIR 2DS4 Expression b | ||
|---|---|---|---|---|
| Median (range) | P* | Median (range) | P* | |
| Donor Type | ||||
| Sibling Donor | 346 (0, 15624) | 0.0004 | 2302 (0, 89328) | 0.0002 |
| Unrelated Donor | 95 (0, 701) | 769 (0, 8304) | ||
|
| ||||
| Transplant source | ||||
| Bone Marrow | 94.5 (0, 1038) | 0.04 | 834 (15, 4863) | 0.03 |
| Peripheral Blood Stem Cells | 232 (0, 15624) | 2053.5 (0, 89328) | ||
|
| ||||
| Diagnosis | ||||
| Lymphoid | 178 (0, 2265) | 0.53 | 1561 (0, 15107) | 0.91 |
| Myeloid | 228 (0, 15624) | 1488 (0, 89328) | ||
| Other | 1 (0, 1038) | 910 (104, 8304) | ||
|
| ||||
| Disease Status at Transplant | ||||
| 1st Complete Remission/CP | 188.5 (0, 15624) | 0.96 | 2066 (0, 15107) | 0.46 |
| Later CR/Later CP | 224 (6, 1254) | 863 (15, 2725) | ||
| Relapse | 232 (0, 2265) | 2209.5 (81, 5224) | ||
| Induction Failure | 178 (0, 1769) | 1235 (0, 27388) | ||
| MDS, AA, MM, MPD | 194 (0, 6648) | 2041 (104, 89328) | ||
|
| ||||
| Conditioning | ||||
| Fludarabine/Melphalan | 225.5 (0, 2265) | 0.75 | 2033 (0, 39860) | 0.83 |
| Myeloablative | 214.5 (0, 15624) | 1383 (0, 89328) | ||
|
| ||||
| CMV Serology | ||||
| D−/R+ | 76 (0, 1758) | 0.03 | 1452 (0, 8304) | 0.75 |
| D+/R− | 128 (0, 15624) | 2079 (0, 5005) | ||
| D+/R+ | 300 (0, 10023) | 1449 (0, 89328) | ||
|
| ||||
| Acute GVHD Grade | ||||
| 0-I | 188.5 (1758) | 0.17 | 1110 (0, 39860) | 0.55 |
| II-IV | 268.5 (0, 15624) | 1561 (0, 89328) | ||
|
| ||||
| Chronic GVHD Grade | ||||
| None | 321 (0, 1769) | 0.53 | 1839 (0, 27388) | 0.83 |
| Limited | 300 (0, 1254) | 1226 (0, 5224) | ||
| Extensive | 194 (0, 15624) | 2033 (0, 89328) | ||
*
Kruskal-Wallis Test;
a
KIR2DS2 genotype;
b
KIR2DS4 genotype.